Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2A, Randomized, Double-Blind Study in Healthy Adults Safety/Immunogenicity Of Hantaan Virus And Puumala Virus DNA Vaccines To Prevent Hemorrhagic Fever Renal Syndrome Using Pharmajet Stratis® Needle-Free Jet Injection Delivery Device

NCT04333459 is registered in ClinicalTrials.gov with U.S. Army Medical Research and Development Command as lead sponsor.

NCT NCT04333459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04333459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2A, Randomized, Double-Blind Study in Healthy Adults Safety/Immunogenicity Of Hantaan Virus And Puumala Virus DNA Vaccines To Prevent Hemorrhagic Fever Renal Syndrome Using Pharmajet Stratis® Needle-Free Jet Injection Delivery Device
Lead sponsor
U.S. Army Medical Research and Development Command
Phase
Phase 2
Overall status
Completed
Start date
August 23, 2021
Completion date
October 15, 2024
Enrollment
132 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hantaan virus nephropathy, puumala virus nephropathy